JP4521187B2 - コンジュゲートされた抗精神病薬およびこれらの使用 - Google Patents

コンジュゲートされた抗精神病薬およびこれらの使用 Download PDF

Info

Publication number
JP4521187B2
JP4521187B2 JP2003530202A JP2003530202A JP4521187B2 JP 4521187 B2 JP4521187 B2 JP 4521187B2 JP 2003530202 A JP2003530202 A JP 2003530202A JP 2003530202 A JP2003530202 A JP 2003530202A JP 4521187 B2 JP4521187 B2 JP 4521187B2
Authority
JP
Japan
Prior art keywords
perphenazine
residue
chemical
catalepsy
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003530202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503423A (ja
JP2005503423A5 (https=
Inventor
アブラハム ヌデルマン，
アダ レファエリ，
イリト ギル−アド，
アブラハム ウェイズマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bar Ilan University
Original Assignee
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bar Ilan University filed Critical Bar Ilan University
Publication of JP2005503423A publication Critical patent/JP2005503423A/ja
Publication of JP2005503423A5 publication Critical patent/JP2005503423A5/ja
Application granted granted Critical
Publication of JP4521187B2 publication Critical patent/JP4521187B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
JP2003530202A 2001-09-27 2002-09-29 コンジュゲートされた抗精神病薬およびこれらの使用 Expired - Fee Related JP4521187B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32493601P 2001-09-27 2001-09-27
PCT/IL2002/000795 WO2003026563A2 (en) 2001-09-27 2002-09-29 Conjugated anti-psychotic drugs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010008725A Division JP2010090170A (ja) 2001-09-27 2010-01-19 コンジュゲートされた抗精神病薬およびこれらの使用

Publications (3)

Publication Number Publication Date
JP2005503423A JP2005503423A (ja) 2005-02-03
JP2005503423A5 JP2005503423A5 (https=) 2006-01-05
JP4521187B2 true JP4521187B2 (ja) 2010-08-11

Family

ID=23265759

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003530202A Expired - Fee Related JP4521187B2 (ja) 2001-09-27 2002-09-29 コンジュゲートされた抗精神病薬およびこれらの使用
JP2010008725A Pending JP2010090170A (ja) 2001-09-27 2010-01-19 コンジュゲートされた抗精神病薬およびこれらの使用
JP2013184566A Pending JP2014015472A (ja) 2001-09-27 2013-09-06 コンジュゲートされた抗精神病薬およびこれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010008725A Pending JP2010090170A (ja) 2001-09-27 2010-01-19 コンジュゲートされた抗精神病薬およびこれらの使用
JP2013184566A Pending JP2014015472A (ja) 2001-09-27 2013-09-06 コンジュゲートされた抗精神病薬およびこれらの使用

Country Status (10)

Country Link
EP (2) EP1429844B1 (https=)
JP (3) JP4521187B2 (https=)
KR (4) KR20100097224A (https=)
CN (2) CN101445494A (https=)
AT (1) ATE541588T1 (https=)
CA (1) CA2461663A1 (https=)
ES (2) ES2399977T3 (https=)
IL (2) IL161083A0 (https=)
MX (1) MXPA04002912A (https=)
WO (1) WO2003026563A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010090170A (ja) * 2001-09-27 2010-04-22 Ramot At Tel Aviv Univ Ltd コンジュゲートされた抗精神病薬およびこれらの使用
US8722923B2 (en) 2008-02-11 2014-05-13 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
US8975251B2 (en) 2009-12-09 2015-03-10 Bar-Ilan University Methods of improving cognitive functions

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
EP2272537A3 (en) 2005-06-07 2014-10-22 Ramot at Tel-Aviv University Ltd. Salts of conjugated psychotropic drugs and processes of preparing same
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
CN101506188B (zh) * 2006-06-22 2014-01-15 雷蒙特亚特特拉维夫大学有限公司 作为具外周系统限制活性药物的五羟色胺再摄取抑制剂
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
EP2051735B1 (en) * 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
EP2101585A4 (en) * 2006-11-30 2011-06-15 Cenerx Biopharma Inc PIVAGABIN DIALKYLAMINOAL CYLTERS AS A MEDICAMENT FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
MX2010014203A (es) 2008-06-20 2011-02-22 Astrazeneca Ab Derivados de dibenzotiazepina y sus usos - 424.
CN105330603A (zh) * 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
AU2014202425B2 (en) * 2009-12-31 2015-11-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
CN107714703A (zh) * 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
US8377929B2 (en) 2010-02-24 2013-02-19 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
EP3476218A1 (en) 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
CN111329865A (zh) * 2020-03-30 2020-06-26 华东理工大学 奋乃静在制备治疗子宫内膜癌的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL227699A (https=) 1957-09-11 1900-01-01
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
GB1460713A (en) * 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3978216A (en) * 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3956493A (en) * 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
GB1540842A (en) * 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
CN1375287A (zh) * 2001-03-16 2002-10-23 王玉万 含氯氰碘柳胺或其钠盐的兽用混悬注射剂
JP4521187B2 (ja) * 2001-09-27 2010-08-11 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲートされた抗精神病薬およびこれらの使用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010090170A (ja) * 2001-09-27 2010-04-22 Ramot At Tel Aviv Univ Ltd コンジュゲートされた抗精神病薬およびこれらの使用
JP2014015472A (ja) * 2001-09-27 2014-01-30 Ramot At Tel Aviv University Ltd コンジュゲートされた抗精神病薬およびこれらの使用
US8722923B2 (en) 2008-02-11 2014-05-13 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US8975251B2 (en) 2009-12-09 2015-03-10 Bar-Ilan University Methods of improving cognitive functions
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same

Also Published As

Publication number Publication date
EP2275143A2 (en) 2011-01-19
ES2379544T3 (es) 2012-04-27
KR20120032547A (ko) 2012-04-05
EP2275143A3 (en) 2011-01-26
JP2005503423A (ja) 2005-02-03
EP1429844B1 (en) 2012-01-18
KR20090130150A (ko) 2009-12-17
CN101445494A (zh) 2009-06-03
JP2014015472A (ja) 2014-01-30
WO2003026563A9 (en) 2004-04-22
IL161083A0 (en) 2004-08-31
ATE541588T1 (de) 2012-02-15
WO2003026563A3 (en) 2004-03-18
EP1429844A4 (en) 2006-06-07
KR101238452B1 (ko) 2013-02-28
JP2010090170A (ja) 2010-04-22
CN100558365C (zh) 2009-11-11
EP1429844A2 (en) 2004-06-23
KR100996239B1 (ko) 2010-11-23
ES2399977T3 (es) 2013-04-04
CA2461663A1 (en) 2003-04-03
MXPA04002912A (es) 2004-07-05
IL202291A0 (en) 2011-07-31
CN1596141A (zh) 2005-03-16
EP2275143B1 (en) 2012-12-19
KR20040062554A (ko) 2004-07-07
KR20100097224A (ko) 2010-09-02
WO2003026563A2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
JP2014015472A (ja) コンジュゲートされた抗精神病薬およびこれらの使用
JP5038126B2 (ja) コンジュゲート化された向精神性薬物およびその使用
JP5284779B2 (ja) コンジュゲート化された向精神薬の新規な塩およびその調製方法
IL161083A (en) Conjugated anti-psychotic drugs of the phenothiazine family and uses thereof
AU2004201240B2 (en) Conjugated Psychotropic Drugs and Uses Thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100507

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100524

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130528

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130528

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140528

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees